IMMUNEERING CORP - CLASS A (IMRX)

IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024

IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024.

IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immuneering (NASDAQ:IMRX) just reported results for the first quarter of 2024.I...

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates...

Immuneering Recognizes Melanoma Awareness Month

Immuneering Recognizes Melanoma Awareness Month

Immuneering Recognizes Melanoma Awareness Month...

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models ...

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference...

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations...

March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was...

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Former Chairman, CEO and Founder of ChemoCentryx, Inc.

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Former Chairman, CEO and Founder of ChemoCentryx, Inc....

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal...

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and...

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a...

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – –...

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation.